GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: LY-3819253 | LY-CoV555 | LY3819253
Compound class:
Antibody
Comment: Bamlanivimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2. It was developed by Eli Lilly, but such is the speed of COVID-19 therapeutic development, there are no peer-reviewed articles that report its design, preclinical or early clinical data.
|
| No information available. |
Summary of Clinical Use  |
| On November 9, 2020 the FDA issued emergency use authorisation (EUA) for bamlanivimab, which allows its use in patients (adult and pediatric) with mild-to-moderate COVID-19 who have received a positive virus test result. Bamlanivimab is administered as a single i.v. dose by a health care professional. Also in trial in combination with etesevimab (LY3832479, LY-CoV016). The EUA was revoked in the US in April 2021. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04603651 | Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19 | Expanded Access | Eli Lilly and Company | ||
| NCT04518410 | ACTIV-2: A Study for Outpatients With COVID-19 | Phase 2/Phase 3 Interventional | National Institute of Allergy and Infectious Diseases (NIAID) | ||
| NCT04497987 | A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff | Phase 3 Interventional | Eli Lilly and Company | ||
| NCT04427501 | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness | Phase 2 Interventional | Eli Lilly and Company | ||
